Research Grade Bemarituzumab
Product Sizes
1 mg
£506.00
DHD47901-1MG
5 mg
£1169.00
DHD47901-5MG
25 mg
£1641.00
DHD47901-25MG
About this Product
- SKU:
- DHD47901
- Additional Names:
- FPA144 ,FPA-144, FPA114-A, CAS: 1952272-74-0
- Buffer:
- 0.01M PBS, pH 7.4.
- translate.label.attr.clone:
- Bemarituzumab
- Clonality:
- Recombinant Monoclonal
- Concentration:
- 1 mg/ml
- Extra Details:
- Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to 2b Isoform of thefibroblast growth factor receptor (FGFR2b). Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22. Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism, thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors. Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIIIA receptor expressed on natural killer cells, enabling enhanced antibody-dependent cellmediated cytotoxicity.
- Host:
- Human
- Immunogen:
- K-sam, KSAM, CD332, Keratinocyte growth factor receptor, Fibroblast growth factor receptor 2, FGFR-2, FGFR2, KGFR, BEK
- Isotype:
- IgG1, kappa
- Physical State:
- Liquid
- Purity:
- >95%
- Purification:
- Protein A/G purified from cell culture supernatant.
- Reactivities:
- Human
- Shipping Conditions:
- Blue Ice
- Source:
- XtenCHO
- Storage Conditions:
- -20[o]C Avoid freeze/thaw cycles., 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- AntibodySystem
- Type:
- Antibody: Recombinant Antibodies
- Manufacturer's Data Sheet:371.html
